Pfizer will receive around £2.7 billion in aggregate from Haleon from an offering and a share buyback.

Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding ...

Pfizer's stake sale in British consumer healthcare company Haleon has been upsized by 100 million shares to 640 million ...

Pfizer's stake sale in British consumer healthcare company Haleon has been upsized by 100 million shares to 640 million ...

Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...

U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where ...

Pfizer anticipates revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization. See why ...

The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...

Pfizer remains an attractive capital return play with a 10X P/E ratio, despite concerns about post-COVID revenue declines.

Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...

Pfizer Inc. plans to sell 540 million worth of shares in Haleon Plc, as it pares back its holding in the UK consumer health ...